AFMD - Affimed updates on product pipeline and cash balances
Affimed N.V. (AFMD) reports cash and cash equivalents of ~€147M as of Dec. 31st, that provides cash runway into the first half of 2023.Clinical stage program, AFM13 (CD30/CD16A ICE), a Phase 2 registration-directed study of AFM13 as monotherapy in relapsed or refractory patients with CD30-positive peripheral T-cell lymphoma (pTCL), remains ahead of schedule. The company expects to complete the interim data analysis during the 1H21.The first dose cohort of AFM13-104, an investigator sponsored Phase 1 study at The University of Texas MD Anderson Cancer Center evaluating the tolerability and efficacy of AFM13 preloaded cord blood-derived NK cells (cbNK) followed by weekly AFM13 monotherapy in patients with refractory CD30 expressing lymphomas, is ongoing.AFM24 (EGFR/CD16A ICE) AFM24-101, a Phase 1/2a clinical trial of AFM24, the EGFR/CD16A targeted ICE for treatment of patients with EGFR-expressing solid tumors, has completed dose cohort 3 (80 mg per patient) without showing dose limiting side effects and patients
For further details see:
Affimed updates on product pipeline and cash balances